128 related articles for article (PubMed ID: 8157719)
1. Magnetic resonance imaging evaluation of adipose tissue and muscle tissue mass in children with growth hormone (GH) deficiency, Turner's syndrome, and intrauterine growth retardation during the first year of treatment with GH.
Leger J; Carel C; Legrand I; Paulsen A; Hassan M; Czernichow P
J Clin Endocrinol Metab; 1994 Apr; 78(4):904-9. PubMed ID: 8157719
[TBL] [Abstract][Full Text] [Related]
2. Human growth hormone treatment of short-stature children born small for gestational age: effect on muscle and adipose tissue mass during a 3-year treatment period and after 1 year's withdrawal.
Leger J; Garel C; Fjellestad-Paulsen A; Hassan M; Czernichow P
J Clin Endocrinol Metab; 1998 Oct; 83(10):3512-6. PubMed ID: 9768656
[TBL] [Abstract][Full Text] [Related]
3. Body composition and physical fitness are major determinants of the growth hormone-insulin-like growth factor axis aberrations in adult Turner's syndrome, with important modulations by treatment with 17 beta-estradiol.
Gravholt CH; Naeraa RW; Fisker S; Christiansen JS
J Clin Endocrinol Metab; 1997 Aug; 82(8):2570-7. PubMed ID: 9253336
[TBL] [Abstract][Full Text] [Related]
4. Decreased growth hormone response to growth hormone-releasing hormone in Turner's syndrome: relation to body weight and adiposity.
Reiter JC; Craen M; Van Vliet G
Acta Endocrinol (Copenh); 1991 Jul; 125(1):38-42. PubMed ID: 1872123
[TBL] [Abstract][Full Text] [Related]
5. Slow baseline growth and a good response to growth hormone (GH) therapy are related to elevated spontaneous GH pulse frequency in girls with Turner's syndrome.
Kamp GA; Kuilboer MM; Wynne HJ; Rongen-Westerlaken C; Johnson ML; Veldhuis JD; Wit JM
J Clin Endocrinol Metab; 1993 Jun; 76(6):1604-9. PubMed ID: 8501169
[TBL] [Abstract][Full Text] [Related]
6. Plasma growth hormone-binding protein activity, insulin-like growth factor I, and its binding protein levels in patients with Turner's syndrome: effect of short- and long-term recombinant human growth hormone administration.
Saggese G; Federico G; Cinquanta L
Pediatr Res; 1995 Jan; 37(1):106-11. PubMed ID: 7535419
[TBL] [Abstract][Full Text] [Related]
7. Decreased metabolic clearance of endogenous growth hormone and specific alterations in the pulsatile mode of growth hormone secretion occur in prepubertal girls with Turner's syndrome. Genentech Collaborative Group.
Veldhuis JD; Sotos JF; Sherman BM
J Clin Endocrinol Metab; 1991 Nov; 73(5):1073-80. PubMed ID: 1939522
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone therapy in Turner's syndrome: an update on final height. Genentech National Cooperative Study Group.
Rosenfeld RG
Acta Paediatr Suppl; 1992 Sep; 383():3-6; discussion 7. PubMed ID: 1458013
[TBL] [Abstract][Full Text] [Related]
9. Presence of magnetic resonance imaging abnormalities of the hypothalamic-pituitary axis is a significant determinant of the first 3 years growth response to human growth hormone treatment in prepubertal children with nonacquired growth hormone deficiency.
Zenaty D; Garel C; Limoni C; Czernichow P; Léger J
Clin Endocrinol (Oxf); 2003 May; 58(5):647-52. PubMed ID: 12699449
[TBL] [Abstract][Full Text] [Related]
10. Growth-promoting effect of growth hormone and low dose ethinyl estradiol in girls with Turner's syndrome.
Vanderschueren-Lodeweyckx M; Massa G; Maes M; Craen M; van Vliet G; Heinrichs C; Malvaux P
J Clin Endocrinol Metab; 1990 Jan; 70(1):122-6. PubMed ID: 2294126
[TBL] [Abstract][Full Text] [Related]
11. Insulin, insulin-like growth factor-binding protein-1, and sex hormone-binding globulin in patients with Turner's syndrome: course over age in untreated patients and effect of therapy with growth hormone alone and in combination with oxandrolone.
Haeusler G; Schmitt K; Blümel P; Plöchl E; Waldhör T; Frisch H
J Clin Endocrinol Metab; 1996 Feb; 81(2):536-41. PubMed ID: 8636264
[TBL] [Abstract][Full Text] [Related]
12. Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone.
Nilsson KO; Albertsson-Wikland K; Alm J; Aronson S; Gustafsson J; Hagenäs L; Häger A; Ivarsson SA; Karlberg J; Kriström B; Marcus C; Moell C; Ritzen M; Tuvemo T; Wattsgård C; Westgren U; Westphal O; Aman J
J Clin Endocrinol Metab; 1996 Feb; 81(2):635-40. PubMed ID: 8636281
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone and craniofacial changes: preliminary data from studies in Turner's syndrome.
Simmons KE
Pediatrics; 1999 Oct; 104(4 Pt 2):1021-4. PubMed ID: 10506256
[TBL] [Abstract][Full Text] [Related]
14. [Growth hormone for Turner's syndrome].
Fishman A; Hochberg Z
Harefuah; 1991 Nov; 121(9):281-6. PubMed ID: 1800273
[TBL] [Abstract][Full Text] [Related]
15. Prediction of the growth response in children with various growth disorders treated with growth hormone: analyses of data from the Kabi Pharmacia International Growth Study. International Board of the Kabi Pharmacia International Growth Study.
Ranke MB; Guilbaud O; Lindberg A; Cole T
Acta Paediatr Suppl; 1993 Sep; 82 Suppl 391():82-8; discussion 89. PubMed ID: 8219483
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone bioactivity in girls with Turner's syndrome: correlation with insulin-like growth factor I.
Foster CM; Borondy M; Markovs ME; Hopwood NJ; Kletter GB; Beitins IZ
Pediatr Res; 1994 Feb; 35(2):218-22. PubMed ID: 7513079
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of 20-kilodalton human growth hormone (GH) are parallel those of 22-kilodalton human GH in normal and short children.
Ishikawa M; Yokoya S; Tachibana K; Hasegawa Y; Yasuda T; Tokuhiro E; Hashimoto Y; Tanaka T
J Clin Endocrinol Metab; 1999 Jan; 84(1):98-104. PubMed ID: 9920068
[TBL] [Abstract][Full Text] [Related]
18. Pulsatile growth hormone release in Turner's syndrome and short normal children.
Ghizzoni L; Lamborghini A; Ziveri M; Volta C; Panza C; Balestrazzi P; Bernasconi S
Acta Endocrinol (Copenh); 1990 Sep; 123(3):291-7. PubMed ID: 2239077
[TBL] [Abstract][Full Text] [Related]
19. [Other indications for growth hormone treatment: chronic kidney failure and Turner's syndrome].
Martul P; Rodríguez Soriano J; Vallo A; Oliveros R; Igea J; Loridan L; Pineda J
An Esp Pediatr; 1992 Jun; 36 Suppl 48():178-81. PubMed ID: 1636962
[TBL] [Abstract][Full Text] [Related]
20. Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: analysis of data from KIGS (Pfizer International Growth Database).
Darendeliler F; Ranke MB; Bakker B; Lindberg A; Cowell CT; Albertsson-Wikland K; Reiter EO; Price DA
Horm Res; 2005; 63(1):40-7. PubMed ID: 15627781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
